Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmuniCell in Advanced Melanoma, Renal Cell Cancer, or NSCLC
NCT02459067Phase 2Terminated
- Sponsor
- TC BioPharm
- Start
- Dec 2015
- Primary completion
- Nov 2018
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of immunicell in melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), sponsored by TC BioPharm. Started Dec 2015; status: terminated.
02
Drugs
immunicell
03
Conditions
melanomarenal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02459067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02459067.